Trial Profile

An open-label, 2-treatment, fixed-sequence drug-drug interaction phase 1 study evaluating the impact of multiple oral doses of 700 mg rivoceranib on the single-dose PK of CYP enzyme substrates

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 24 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoceranib (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Vitamin K; Warfarin
Indications Adenoid cystic carcinoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer; Uterine cancer
Focus Pharmacokinetics

24 May 2023 New trial record
19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com